1. Generics Bulletin

Patent Pool Expands Remit To COVID-19

As WHO Welcomes Proposal Covering Rights To Tests, Medicines And Vaccines

 
• By Akriti Seth

The Medicines Patent Pool has expanded its mandate to include treatments that will aid the global response to the coronavirus pandemic.

Face_Masks_Covid19
The MPP and Unitaid step up to help the WHO through the coronavirus crisis • Source: Shutterstock

The board of the Medicines Patent Pool has announced that the MPP will temporarily expand its mandate to “include any health technology that could contribute to the global response to coronavirus and where licensing could facilitate innovation and access.”

The MPP was founded and is funded by Unitaid, a hosted partnership of the World Health Organization that invests in innovations to prevent, diagnose and treat diseases such as HIV/AIDS, tuberculosis and malaria “more quickly, affordably and effectively

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.